Type 2 diabetes mellitus (T2DM) has become the third main chronic non-infectious disease following tumors and cardiovascular disease. Diagnosis of diabetes can help researchers efficiently analyze the causes of diabetes and advance the development of therapies. Ace Therapeutics can provide diagnostic development service of T2DM with more efficient function analysis.
T2DM is associated with insulin resistance. The most important complications are heart disease, stroke, kidney failure (nephropathy), peripheral nerve damage and peripheral vascular disease. Classical diagnostic markers (blood glucose and HbA1C) are generally detected once metabolic imbalance has already set in. There is development of untargeted and targeted metabolomic techniques to examine the metabolite profiles of T2DM to find new diagnostic markers.
The Diagnosis of Diabetes (Petersmann, A.; et al. Experimental and Clinical Endocrinology & Diabetes. 2019)
The currently used therapies aim to delay progression of T2DM. There are a number of recognized biomarkers for type 2 diabetes mellitus risk, such as fasting plasma glucose and glycated hemoglobin A1c (HbA1c), triglycerides, adiponectin and inflammatory markers.
Impact of Hyperinsulinemia and T2DM on IFN-I Signaling (Veronica, V.; et al. Trends in Endocrinology & Metabolism. 2022)
The routine diagnosis of T2DM is generally based on the plasma glucose values in a fasted state (FPG) and 2 hours after an oral intake of 75 g glucose (OGTT). Metabolomics is a potential tool for the discovery of new biomarkers in the early diagnosis of diseases. For example, the blood samples from type 2 diabetes mellitus model can employ chemistry analysis, 1D 1H NMR and mass spectroscopy (FIA-MS/MS and LC-MS/MS) techniques to identify markers.
The Effective diagnostics can help clients complete their disease model analysis more efficiently and better assessment of therapeutics and drug targets of T2DM. Ace Therapeutics can provide the T2DM diagnostic development services for different diagnostic markers (glucose, HbAlc, C-peptide, autoantibodies, proteins, nucleic acids, and metabolites, et al.).
In addition, we provide T2DM biomarker development and T2DM therapy development service for our clients worldwide.
Highly Customizable
One-stop Services
High Quality
Professional Team
Ace Therapeutics offers cost-effect and high-quality research services related to type 2 diabetes mellitus diagnostic development for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.